The key to big gains last year? Start off small.
News & Analysis: XOMA
These three biotech stocks helped a lot of investors get rich this year. Are there more gains ahead?
XOMA's third quarter financial results failed to ignite investor enthusiasm today.
Wall Street has cast these three biotech stocks to the proverbial scrap heap over the past five years, but a big rebound may soon be in order.
XOMA shareholders press the launch button after the company begins the (approximate) countdown to a major news event.
XOMA Corp. released its first-quarter earnings results after the closing bell last night, but it was a single sentence from management, not its actually quarterly results, that has investors so excited today.
Thinking of investing in this high risk, high reward biotech stock? Here are three things you need to know first.
Neuralstem, Inc., Depomed Inc., and Xoma Corp. have news that could move them this year.
Xoma Corporation could release late stage trial data that could significantly move the stock.
XOMA shareholders get blindsided by a combination of emotions and fundraising. Find out whether or not this dip is a reason to buy or a warning to keep your distance.